NYSE
BSX
Last Price
US $42.68
KEY FIGURES
MKT CAP
$65.7B
EPS
TTM
$2.39
PEG
TTM
0.25x
P/E
TTM
18.43x
P/S
TTM
3.27x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
14.82%
Return on equity
ROIC: 9.90%
Valuation History
18.4X
Price to Earnings
EV/EBITDA: 13.3X
Cash flow
Profit margin
15.16%
(FY vs FY)
EBITDA Y/Y
27.55%
(FY vs FY)
Cash flow Y/Y
26.44%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $42.68
-13.99%
Default assumptions
EBITDA Multiple
Fair Value
Market $42.68
-75.14%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Boston Scientific Corporation cash flow to debt ratio of 36.51% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial stability - Healthy cash flow growth.
Boston Scientific Corporation's free cash flow has increased 38.30% from $2.65G last year to $3.66G, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Boston Scientific Corporation's debt to equity ratio is 0.43, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Boston Scientific Corporation's debt has decreased relative to shareholder equity from 0.51 last year to 0.43 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Boston Scientific Corporation has a net debt to EBITDA ratio of 2.03x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Boston Scientific Corporation's interest coverage ratio of 11.62 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
Boston Scientific Corporation's profit margin has increased (55.68%) in the last year from 11.07% to 17.23%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Boston Scientific Corporation's short-term assets of $8.79G exceed its short-term liabilities of $5.44G
Increasing performance - ROA.
Boston Scientific Corporation's return on assets of 8.01% is higher than the 5.00% threshold, indicating efficient asset utilization
Decreasing performance - Absolute return on equity.
Boston Scientific Corporation's return on equity of 14.82%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Boston Scientific Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Boston Scientific Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Boston Scientific Corporation has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Boston Scientific Corporation has a free cash flow yield of 5.56%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Boston Scientific Corporation's yearly earnings has increased 55.66% since last year from $1.85G to $2.89G, signaling increasing performance
Increasing performance - Healthy revenue growth.
Boston Scientific Corporation's yearly revenue has increased 19.87% since last year from $16.75G to $20.07G, signaling increasing performance
Increasing performance - ROIC.
ROIC 9.90% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Increasing performance - 3-year revenue CAGR.
Boston Scientific Corporation's 3-year revenue CAGR of 16.54% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Boston Scientific Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Boston Scientific Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Boston Scientific Corporation is overvalued relative to its fair value price of 36.71 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Boston Scientific Corporation has an earnings yield of 5.41%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Boston Scientific Corporation is overvalued relative to its fair value price of 10.61 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Boston Scientific Corporation has an EV/EBITDA ratio of 13.30x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Boston Scientific Corporation has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Boston Scientific Corporation has a price-to-book ratio of 2.54x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Boston Scientific Corporation has a price-to-sales ratio of 3.19x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue